TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8214728
Drug: Epidural nalbuphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural nalbuphine (NB) 10 mg
Study: 8214728
Drug: Oral naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral naltrexone (NX) 6 mg
Study: 29716655
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 mg once daily for the first 6 weeks, then 10 mg once daily for the next 6 weeks)
Study: 24403544
Drug: No Hib
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Hib conjugate vaccine booster
Study: 18540741
Drug: 1-session exposure-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-session exposure-based treatment plus inactive pill with sedating herb description
Study: 18540741
Drug: 1-session exposure-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-session exposure-based treatment plus inactive pill with stimulating herb description
Study: 18540741
Drug: 1-session exposure-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-session exposure-based treatment plus inactive pill with placebo description
Study: 18540741
Drug: 1-session exposure-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-session exposure-based treatment
Study: 10082241
Drug: CCK4 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCK4 (25 microg, i.v. injection)
Study: 8851038
Drug: Cetirizine 10
Normalized name: cetirizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 10 mg once a day
Study: 2261015
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide 0.1% cream with Duoderm dressing
Study: 2261015
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide 0.1% cream with Actiderm dressing
Study: 366723
Drug: Diflunisal 250
Normalized name: diflunisal 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal 250 mg to 375 mg twice daily
Study: 366723
Drug: Aspirin 500
Normalized name: aspirin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 500 mg to 750 mg four times daily
Study: 31260678
Drug: 37.5 mg
Normalized name: pemoline 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 37.5 mg prednisolone/d for 5 days
Study: 23485142
Drug: Buckwheat crackers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buckwheat crackers (daily for 1 week)
Study: 1540093
Drug: Norfloxacin, 500-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin, 500-mg suspension every 8 hours, and nystatin, 1 million units every 6 hours
Study: 1540093
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo solutions administered through a nasogastric tube
Study: 25761488
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m² intravenously every 3 weeks
Study: 25761488
Drug: Gefitinib 250
Normalized name: gefitinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib 250 mg/day orally
Study: 21850515
Drug: Choice over
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choice over treatment options (two pain-relieving treatments, same inert ointment mixture)
Study: 21850515
Drug: No choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: No choice over treatment options (two pain-relieving treatments, same inert ointment mixture)
Study: 21850515
Drug: Control condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition (no treatment expectation)
Study: 10930905
Drug: OAC (omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC (omeprazole 20 mg, amoxycillin 1500 mg, clarithromycin 600 mg for 7 days)
Study: 10930905
Drug: OAC +
Normalized name: Oral Anticoagulant Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC + CET (OAC plus cetraxate 600 mg for 7 days)
Study: 9283508
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (treated in the usual manner)
Study: 8436150
Drug: isradipine SRO
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: isradipine SRO 5 mg once daily
Study: 26817533
Drug: levodopa‐carbidopa intestinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: levodopa‐carbidopa intestinal gel
Study: 26817533
Drug: oral levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: oral levodopa treatment
Study: 25359307
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine (Yi‐Qi‐Jian‐Pi and Qu‐Tan‐Hua‐Zhuo granule) plus conventional medicine
Study: 25359307
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine (Yi‐Qi‐Jian‐Pi and Qu‐Tan‐Hua‐Yu granule) plus conventional medicine
Study: 25359307
Drug: Placebo medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo medicine plus conventional medicine
Study: 25359307
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (including both treatment and control)
Study: 22897374
Drug: 40 %
Normalized name: oxygen 40 %
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 % O2 + 60 % N2O, 1‐2 % sevoflurane and 50 µg fentanyl + 2 mg vecuronium every 45 minutes
Study: 20708634
Drug: Carriers with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carriers with class S allele (L/S or S/S genotypes)
Study: 20708634
Drug: Non-carriers (L/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-carriers (L/L genotype)
Study: 20708634
Drug: L/S genotype
Approvals — FDA: no, EMA: no, PMDA: no
Description: L/S genotype
Study: 8398959
Drug: 45 ml
Normalized name: ethanol 0.645 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 ml interscalene brachial plexus block with 1.5% mepivacaine, epinephrine, and bicarbonate
Study: 8398959
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml interscalene brachial plexus block with 1.5% mepivacaine, epinephrine, and bicarbonate
Study: 29781549
Drug: Platelets administered
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelets administered before transport to surgery
Study: 27842532
Drug: Silybin 94
Normalized name: silybin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silybin 94 mg + vitamin E 30 mg + phospholipids 194 mg
Study: 20562409
Drug: One-visit root
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-visit root canal therapy (ORCT), n = 202
Study: 20652790
Drug: One-visit root
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-visit root canal therapy (ORCT)
Study: 16398773
Drug: 400 microg
Normalized name: Fentanyl 400 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 microg self-administered vaginal misoprostol
Study: 12927624
Drug: Alfentanil (4.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (4.1 +/- 0.5 mg) administered for 90 min
Study: 10807893
Drug: 1.5 kcal/ml
Normalized name: lactose-reduced food 0.05 gram-1.5 kcal/mL ORAL LIQUID (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 kcal/ml nutritional supplement
Study: 6736345
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment with 2% crude coal tar ointment
Study: 31887854
Drug: Rivastigmine patch
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine patch (10 cm² = 9.5 mg)
Study: 25670764
Drug: pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: pegylated liposomal doxorubicin (30 mg/m²) followed by carboplatin (AUC 5 mg min/ml) every 28 days
Study: 21668741
Drug: Butorphanol (0.016
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol (0.016 mg/kg)
Study: 17005060
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (directed cough)
Study: 12024755
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ARD and CHX rinse
Study: 9263319
Drug: Hydrocortisone 2.5%
Normalized name: HYDROCORTISONE 2.5% OINT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone 2.5% cream once daily + water-in-oil cream once daily
Study: 9263319
Drug: Hydrocortisone 2.5%
Normalized name: HYDROCORTISONE 2.5% OINT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone 2.5% cream twice daily
Study: 8500857
Drug: KCl infusions
Normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: KCl infusions (0.12 and 0.24 mEq/min) with ouabain (2 micrograms/min)
Study: 8500857
Drug: KCl infusions
Normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: KCl infusions (0.12 and 0.24 mEq/min) after salt loading (180 mEq NaCl for 7 days)
Study: 27410923
Drug: Ipilimumab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab (both doses)
Study: 19903780
Drug: GM-CSF (110
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF (110 microg) with multipeptide vaccine
Study: 19903780
Drug: Multipeptide vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multipeptide vaccine without GM-CSF
Study: 19903780
Drug: Multipeptide vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multipeptide vaccine with GM-CSF
Study: 16518754
Drug: Pegylated IFN‐alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated IFN‐alpha 2a and ribavirin combination therapy
Study: 12184546
Drug: Active vitamin
Normalized name: OCTOCRYLENE 70 mg in 1 mL / HOMOSALATE 50 mg in 1 mL / OCTISALATE 50 mg in 1 mL / AVOBENZONE 30 mg in 1 mL TOPICAL CREAM [Garnier SkinActive Vitamin(E) C UV Brightening Daily Broad Spectrum SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active vitamin D treatment (VD(+))
Study: 12184546
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (VD(-))
Study: 2801579
Drug: Protein diet
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein diet (400 kcal/d, 13.2 g nitrogen, 23 mmol potassium)
Study: 2801579
Drug: Glucose diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose diet (400 kcal/d, 16 mmol potassium chloride, multivitamin supplement)
Study: 1102148
Drug: Betamethasone valerate
Normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone valerate aerosol (100 mug into each nostril twice daily)
Study: 31516032
Drug: Glasdegib 100
Normalized name: glasdegib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glasdegib 100 mg once daily plus low-dose cytarabine
Study: 23432600
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (20 mg of omeprazole, 500 mg of clarithromycin, and 1000 mg of amoxicillin orally two times daily)
Study: 21310819
Drug: IL-1 receptor
Normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-1 receptor antagonist (IL-1ra) for 4 weeks
Study: 19583746
Drug: Physostigmine (1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine (1.8 mg)
Study: 17179269
Drug: TAP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP block with 20 mL of 0.375% levobupivacaine
Study: 30172099
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg daily oral edoxaban
Study: 30172099
Drug: VKA-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: VKA-based therapy (international normalized ratio: 2.0-3.0 or 1.6-2.6 in Japan if age ≥ 70 years)
Study: 30172099
Drug: Both edoxaban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both edoxaban and VKA-based therapy
Study: 22727160
Drug: Salmeterol-fluticasone (50/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol-fluticasone (50/100 μg twice daily)
Study: 22727160
Drug: Fluticasone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone (100 μg twice daily)
Study: 19719551
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg 17beta-estradiol + 10 mg dydrogesterone
Study: 19719551
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg 17beta-estradiol + 10 mg dydrogesterone
Study: 12811706
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of nasal sumatriptan
Study: 12811706
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of intravenous ketorolac
Study: 7084138
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oral and written information
Study: 8646433
Drug: Naloxone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (20 mg i.v. infusion)
Study: 8646433
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (RA and controls) after naloxone treatment
Study: 8646433
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (RA and controls) after any treatment
Study: 6337421
Drug: Cephalexin, 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin, 250 mg every six hours for 72 hours
Study: 30004561
Drug: Conventional surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional surgical treatment with posterior approach (Control)
Study: 23131066
Drug: High-rate therapy
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-rate therapy (2.5-second delay at heart rate ≥200 bpm)
Study: 23131066
Drug: Delayed therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed therapy (60-second delay at 170-199 bpm, 12-second delay at 200-249 bpm, 2.5-second delay at ≥250 bpm)
Study: 18490498
Drug: Subcutaneous epoetin
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous epoetin delta
Study: 16283958
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of 2% lidocaine
Study: 16283958
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of 0.5% bupivacaine
Study: 16283958
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of 2% lidocaine and 15 mg of 0.5% bupivacaine
Study: 12467943
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg meta-chlorophenylpiperazine (MCPP)
Study: 9503255
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ipsapirone
Study: 10342343
Drug: Pravastatin 20
Normalized name: pravastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 20 mg per day for 4 months
Study: 7141761
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) pretreatment (p.o. 5.0 g/24 h)
Study: 7141761
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) (1.0 or 1.5 g orally)
Study: 7141761
Drug: Pindolol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (1 mg i.v.)
Study: 22370834
Drug: Neural mobilization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neural mobilization treatment
Study: 18679605
Drug: Dihuang Zhixue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihuang Zhixue Capsule (DZC), 2 to 3 capsules orally, thrice a day for 3 months
Study: 18679605
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CsA), 3 mg/kg per day for 3 months
Study: 18679605
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups after 2 months treatment
Study: 18679605
Drug: After 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: After 3 months treatment
Study: 18679605
Drug: After 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: After 8 weeks treatment
Study: 14506391
Drug: Pre-S2/S HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-S2/S HBV vaccine (GenHevac-B) 20 micro g, 3 intramuscular injections on days 0, 30, and 60
Study: 9391135
Drug: cp‐52 (cold-passaged
Approvals — FDA: no, EMA: no, PMDA: no
Description: cp‐52 (cold-passaged candidate vaccine virus)
Study: 8459987
Drug: Ondansetron (32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (32 mg i.v. single dose/day) plus dexamethasone (20 mg i.v. single dose/day)
Study: 8459987
Drug: Metoclopramide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (2 mg/kg or 1 mg/kg i.v. twice a day) plus dexamethasone (20 mg i.v. single dose/day)
Study: 1279169
Drug: Intravenous iloprost
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous iloprost
Study: 29261568
Drug: Thrombin activatable
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombin activatable fibrinolysis inhibitor level and in vivo markers of fibrinolysis activation (plasmin‐antiplasmin complex, D‐dimer).
Study: 10417499
Drug: Cetirizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (10 mg) plus Cimetidine (400 mg)
Study: 7648219
Drug: Antihypertensive drugs
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive drugs (specific classes not mentioned)
Study: 2134115
Drug: Minaprine (200-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minaprine (200-300 mg daily)
Study: 2134115
Drug: Amitriptyline (50-75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (50-75 mg daily)
Study: 7004723
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of moderate salt restriction and high potassium intake (from 80 to 200 mmol/day)
Study: 22231174
Drug: Subcutaneous unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous unfractionated heparin (SQH), 5,000 units subcutaneously three times daily
Study: 22231174
Drug: Intravenous unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous unfractionated heparin (IVH), titrated to an activated partial thromboplastin time of 40-45 s
Study: 17647293
Drug: Clevudine 30
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clevudine 30 mg daily for 24 weeks
Study: 17102823
Drug: Postoperative craniospinal
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative craniospinal radiation therapy (36Gy+boost 20Gy to the posterior fossa)
Study: 17102823
Drug: Postoperative combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative combination cranio-spinal radiation therapy (same dose as group I) and chemotherapy (vincristine, etoposide, cisplatin)
Study: 17102823
Drug: Postoperative craniospinal
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative craniospinal radiation therapy (group I)
Study: 17102823
Drug: Postoperative combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative combination cranio-spinal radiation therapy and chemotherapy (group II)
Study: 12195129
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg/day (titrated to 100 mg/day)
Study: 12195129
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg/day (titrated to 100 mg/day)
Study: 2198294
Drug: Pentobarbital (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentobarbital (100, 200, and 300 mg)
Study: 28294080
Drug: Bilateral sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral sequential same-day tympanoplasty
Study: 24220392
Drug: Intra-articular injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injections of high-molecular-weight hyaluronic acid (HA)
Study: 21698811
Drug: Alverina citrate
Normalized name: alverine
DrugBank: Alverine (DB01616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alverina citrate 60 mg with Simethicone 300 mg three times daily
Study: 21698811
Drug: Alverina citrate
Normalized name: alverine
DrugBank: Alverine (DB01616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alverina citrate and Simethicone combination
Study: 19233855
Drug: Dual-antiplatelet agents
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-antiplatelet agents with highest tertile aspirin dose
Study: 15303131
Drug: Group G+E
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group G+E (epidural anesthesia combined with general anesthesia)
Study: 15303131
Drug: Group G
Normalized name: Prostaglandin group G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group G (general anesthesia)
Study: 15303131
Drug: Group G+E
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group G+E and Group G
Study: 15303131
Drug: Groups G+E
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Groups G+E and G
Study: 15303131
Drug: Group G
Normalized name: Prostaglandin group G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group G and Group G+E
Study: 11772119
Drug: Tianeptine (12.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tianeptine (12.5mg three times daily)
Study: 11772119
Drug: Paroxetine (20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20mg once daily plus two placebo capsules)
Study: 30165844
Drug: Once-weekly injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly injection of exenatide
Study: 30165844
Drug: Twice-daily injection
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily injection of exenatide
Study: 20937187
Drug: Generic 3-drug
Normalized name: celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generic 3-drug fixed-dose combination (3FDC) formulation of rifampicin